Skip to main content

Table 2 Comparisons of progression-free and overall survival

From: Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

Comparison Before matching After matching
HR 95% CI P-Value HR 95% CI P-Value
Progression-free survival       
Everolimus vs. Placebo 0.38 0.29-0.49 <0.001 0.35 0.24-0.52 <0.001
Sunitinib vs. Placebo 0.42 0.26-0.66 <0.001 0.42 0.26-0.66 <0.001
Everolimus vs. Sunitiniba 0.90 0.53-1.53 0.695 0.84 0.46-1.53 0.578
Overall survival       
Everolimus vs. Placebo in A6181111 0.53 0.35-0.78 0.002 0.61 0.38-0.98 0.042
Everolimus vs. Sunitinib 0.69 0.46-1.05 0.087 0.81 0.49-1.31 0.383
  1. Notes:
  2. aComparison based on the HR for everolimus vs. placebo divided by the HR for sunitinib vs. placebo.